reports
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host We...
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy – Webinar to be held Wednesday, December 17, 2025, at 1:00 p.m. ET – SAN DIEGO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced that Parent Project Muscular Dystrophy (PPMD) will host a community webinar to share and discuss positive topline results from Capricor’s Phase 3 HOPE-3 trial evaluating Deramiocel, the Company’s...
Capricor Therapeutics Announces Pricing of $150 Million Public Offerin...
Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced the pricing of its underwritten public offering of 6,000,000 shares of common stock at a public offering price of $25.00 per share. Capricor also granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock at the public offering price, less the underwriting discounts...
Capricor Therapeutics Announces Proposed Public Offering of Common Sto...
Capricor Therapeutics Announces Proposed Public Offering of Common Stock SAN DIEGO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced the commencement of a proposed underwritten public offering of shares of its common stock. In addition, Capricor intends to grant the underwriters a 30-day option to purchase an additional number of shares of common stock equal to 15% of the aggregate number of shares of its common stock sold in the public offering. The proposed...
Capricor Therapeutics Announces Positive Topline Results from Pivotal ...
Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy Pivotal Phase 3 randomized, double-blind, placebo-controlled study (n=106) met the primary endpoint (PUL v2.0) and the key secondary cardiac endpoint (LVEF), both achieving statistical significance (p=0.03 and p=0.04, respectively)Statistical significance was achieved in all type 1 error controlled secondary endpoints Results demonstrate clinically meaningful and statistically significant skeletal and cardiac benefits, supporting Deramiocel as a potential f...
Capricor Therapeutics Presents New Data Demonstrating a Scalable Frame...
Capricor Therapeutics Presents New Data Demonstrating a Scalable Framework for Loading Therapeutic Oligonucleotides into Exosomes at AAEV 2025 --Findings support the versatility of Capricor’s exosome technology, enabling efficient and scalable loading of siRNAs and PMOs to support future clinical development-- SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- ., (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced new data describing a scalable framework for loading therapeutic small interfering RNAs (siRNA) and phosphorodiamid...
Capricor Therapeutics Reports Third Quarter 2025 Financial Results and...
Capricor Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update Topline results from pivotal HOPE-3 Phase 3 study (n=105) of Deramiocel for the treatment of Duchenne muscular dystrophy expected in the coming weeks (Q4 2025)Pending the results of the topline data from the HOPE-3 study, the Company expects to resubmit its BLA, leveraging the data in support of its application for approvalCommercial launch preparations underway to support potential approval and market introduction of Deramiocel in 2026NIAID-sponsored Phase 1 clinical trial underway with Stealth...
Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines De...
Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel –Publication highlights Deramiocel’s anti-fibrotic activity and describes a validated potency assay supporting quality control and product consistency in late-stage development– SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: CAPR), a biotechnology company developing cell and exosome-based therapies for rare diseases, today announced the publication in Biomedicines, an international peer-reviewed journal, descri...
Capricor Therapeutics to Present Third Quarter 2025 Financial Results ...
Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10 Company to Host Conference Call on November 10, 2025, at 4:30 p.m. ET SAN DIEGO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will release its financial results for the third quarter ended September 30, 2025, after the market close on Monday, November 10, 2025. Management will then host a webcast and conference call at 4:30 p....
Capricor Therapeutics Provides Regulatory Update on Deramiocel Program...
Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting FDA and Capricor aligned on endpoints for HOPE-3 pivotal trialHOPE-3 pivotal trial completed; topline data expected mid-Q4 2025 to support BLA resubmissionCompany preparing to resubmit CRL response under the current BLAConference call and webcast scheduled for today at 8:30 a.m. ET SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today annou...
Capricor Therapeutics Responds to FDA Posting of Complete Response Let...
Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today issued a statement regarding the U.S. Food and Drug Administration’s (FDA) public posting of its Complete Response Letter (CRL) for the Biologics License Application (BLA) for Deramiocel, the Company’s investigational cell therapy for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). The Com...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
PSTG PURE STORAGE INC. CLASS A
PAHC PHIBRO ANIMAL HEALTH CORPORATION CLASS A
NTAP NETAPP INC.
LPTH LIGHTPATH TECHNOLOGIES INC. CL A
A AGILENT TECHNOLOGIES INC.
AGX ARGAN INC.
ELF E.L.F. BEAUTY INC.
CHCI COMSTOCK HOLDING COMPANIES
RCMT RCM TECHNOLOGIES
STNE STONECO
CSTL CASTLE BIOSCIENCES
SOFI SOFI TECHNOLOGIES INC
IMRX IMMUNEERING CORP
DSGN DESIGN THERAPEUTICS INC
FTAI FORTRESS TRANSN & INFRAS INVS LLC
ASPI ASP ISOTOPES INC
FTREV FORTREA HOLDINGS INC.
KRRO KORRO BIO INC
RAPP RAPPORT THERAPEUTICS INC
ALMU AELUMA INC
RHLD RESOLUTE HOLDINGS MANAGEMENT INC
ASST ASSET ENTITIES INC
SNDK SANDISK CORP
INFU MULTI UNITS LU - AMUNDI US INFLATION EXPECTATIONS 10Y
Capricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinic...
Capricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Novel Exosome-Based Vaccine First-in-human trial of Capricor’s StealthX™ vaccine initiated under HHS’s Project NextGenTrial conducted and funded by the National Institute of Allergy and Infectious Diseases (NIAID) SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that the first subjects have been dosed in a Phase 1 clinical trial evaluating its StealthX™ exosome-based va...
Capricor Therapeutics Reports Second Quarter 2025 Financial Results an...
Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update Type A meeting with U.S. FDA scheduled to discuss Deramiocel BLA and path toward potential approvalCapricor seeks to resubmit its BLA based on its existing dataset, with HOPE-3 data (expected in Q4 2025) potentially serving as supportive and confirmatory evidence, pending regulatory guidanceAll 483 observations noted in the Pre-License Inspection have been resolved and accepted by the FDAFDA clears IND for StealthX™ exosome-based vaccine; NIAID has initiated the Phase 1 clinical trial Cash bala...
Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA
Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA – Second Quarter 2025 Financial Results and Corporate Update Rescheduled to Monday, August 11, 2025, at 4:30 p.m. ET – SAN DIEGO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that a Type A meeting with the U.S. Food and Drug Administration (FDA) has been scheduled to discuss the regulatory path for its Biologics License Application (BLA) for Deramiocel, the Company’s lead cel...
Carnival Corp: 1 director
A director at Carnival Corp sold 12,500 shares at 29.753USD and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
Capricor Therapeutics to Present Second Quarter 2025 Financial Results...
Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13 – Company to Host Conference Call on August 13, 2025, at 4:30 p.m. ET – SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will release its financial results for the second quarter ended June 30, 2025, after the market close on Wednesday, August 13, 2025. Management will then host a webcast and conference call at 4:30 p.m....
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host We...
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments in the Deramiocel Program for the Treatment of Duchenne Muscular Dystrophy – Webinar to be held on Tuesday, July 29, 2025, at 1:00 p.m. ET – SAN DIEGO, July 28, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that it will host a webinar in collaboration with Parent Project Muscular Dystrophy (PPMD) to review the current status of Capricor’s Biologics License Application ...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
More Breakouts and Risk-On Developments We remain near-term bullish since our 4/22/25 Compass, and our intermediate-term outlook remains bullish as well (as of our 5/14/25 Compass). We will maintain our bullish intermediate-term outlook as long as market dynamics remain healthy and the SPX is above 5700-5785, though we believe there is a low probability that this level gets tested any time soon. Short-term supports on the SPX include the 20-day MA (currently 6233), 6200, 6100-6150, and 6028-605...
EME EMCOR GROUP
STRL STERLING CONSTRUCTION COMPANY INC.
PWR QUANTA SERVICES INC.
MTZ MASTEC INC.
GVA GRANITE CONSTRUCTION INCORPORATED
DY DYCOM INDUSTRIES INC.
BWXT BWX TECHNOLOGIES INC.
FLR FLUOR CORPORATION
MYRG MYR GROUP INC.
AGX ARGAN INC.
ROAD CONSTRUCTION PARTNERS
IESC IES HOLDINGS INC.
SNEX STONEX GROUP INC
HOOD ROBINHOOD MARKETS INC
COIN COINBASE GLOBAL INC
J JACOBS SOLUTIONS INC.
PRIM PRIME ENERGY P.E. LTD
BULL WEBULL CORPORATION
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for...
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy FDA issued Complete Response Letter Capricor plans to resubmit its BLA to include data from the ongoing Phase 3 HOPE-3 trial in Q3 2025 to continue pursuing the indication for the treatment of cardiomyopathy associated with Duchenne muscular dystrophyFDA advised Capricor to request a meeting to determine next steps toward potential approvalConference call and webcast scheduled for today at 8:30 a.m. ET SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CAPR), a biotechnology company dev...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.